Physician profile
David Ahdoot
NPI 1023210432
$17,637.72
in general payments reported to CMS, 2019-2025
36 companies · $2,291 in 2025
The $2,291 reported for 2025 was more than what 95% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $840 · 2021: $1,154 · 2022: $744 · 2023: $417 · 2024: $1,811 · 2025: $2,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,800 · Food and Beverage: $1,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,800.00 |
| Food and Beverage | $1,718.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $10,912.04 | 2019-2025 | Ubrelvy, Lo Loestrin Fe |
| Mimedx Group, INC. | $2,800.00 | 2024-2025 | Bovine Collagen |
| Intuitive Surgical, INC. | $636.65 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $478.19 | 2023-2025 | Gemtesa, Myfembree |
| Uroviu Corporation | $470.10 | 2022-2023 | Uro-G Flexible Cystoscope |
| Exeltis, USA INC. | $228.48 | 2019-2025 | Slynd |
| Sk Life Science, INC. | $198.94 | 2025 | |
| Allergan, INC. | $185.28 | 2019-2020 | |
| Therapeuticsmd, INC. | $181.57 | 2019-2022 | |
| Astellas Pharma US INC | $174.52 | 2019-2022 | |
| Hologic Sales and Service, LLC | $157.78 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Pfizer INC. | $144.49 | 2020-2025 | |
| Bausch Health US, LLC | $125.48 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $117.29 | 2021-2025 | |
| Sage Therapeutics, LLC | $115.71 | 2024-2025 | Zurzuvae |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $82.29 | 2021-2022 | |
| Evofem Biosciences, INC. | $65.87 | 2020-2021 | |
| Baxter Healthcare | $54.87 | 2024 | Perclot |
| Boston Scientific Corporation | $47.34 | 2023 | Bodyguardian, Lux-Dx Insertable Cardiac Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $46.99 | 2019-2022 | |
| Avion Pharmaceuticals | $42.29 | 2022-2023 | Balcoltra |
| Biofire Diagnostics, LLC | $42.04 | 2019-2020 | |
| Mission Pharmacal Company | $40.95 | 2019 | |
| Vertical Pharmaceuticals, LLC | $36.98 | 2019 | |
| Shield Therapeutics INC | $32.65 | 2023 | Accrufer |
| Emd Serono, INC. | $26.93 | 2025 | |
| Genentech USA, INC. | $26.68 | 2025 | Ocrevus Zunovo |
| Duchesnay USA Incorporated | $24.35 | 2019 | |
| Millicent US INC | $22.89 | 2025 | Femlyv, Intrarosa |
| Minerva Surgical, INC | $20.03 | 2019 | |
| Agile Therapeutics, INC. | $18.91 | 2022 | |
| Channel Medsystems, INC. | $18.61 | 2022 | |
| Novo Nordisk INC | $17.37 | 2025 | Wegovy, Saxenda |
| Coopersurgical, INC. | $17.35 | 2025 | Paragard T 380a |
| Endo Pharmaceuticals INC. | $13.14 | 2020 | |
| Lupin INC. | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ahdoot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.